Multi-center remote glucose monitoring at COVID-19 Intensive Care Units. Case report in Argentina.

FABRICIO GARELLI; DELFINA ARAMBARRI; LEANDRO MENDOZA; NICOLÁS ROSALES; EMILIA FUSHIMI; BATTISTA, HERNÁN DE; RICARDO SANCHEZ PEÑA; LUIS GROSEMBACHER; GABRIELA KROCHIK

Conferencia; 14th International Conference on Advanced Technology & Treatments for Diabetes.; 2021

Background and aims: This work analyzes the feasibility and relevance of remote and on-line glucose monitoring in both Intensive Care Units (ICU) and quarantined ambulatory patients using an own platform originally developed by the group to continue with artificial pancreas clinical trials [1]. Method: The monitoring platform was developed from open-source resources and is available on- line (www.insumate.com.ar), it runs on an own server and can manage up to 40 simultaneous patients in each health center. Furthermore, it allows using different CGMs and is completely configurable in a remote way. The first four cases using the platform at COVID-19 ICU in Argentina are reported. Four critical patients have been monitored using Dexcom G6, two children and two adults, together with an ambulatory patient using FreeStyle Libre to test the platform versatility and long-term performance. Results: Fig. 1 presents the ICU monitored cases and their outcomes. The collected data indicates that the use of this new platform aids healthcare personnel lower the users mean BG (blood glucose) levels while diminishing their exposure. All ICU patients have recovered or have been metabolically controlled by the date of the submission of this abstract. The ambulatory patient completed 198 days of remote monitoring without any adverse event (received samples: 96,37%).Conclusions: An adequate glycemic control and a favorable clinical evolution were observed in all patients. Also, a great acceptance and adherence of ICU healthcare personnel has been found.